Pharma BD Deal Intelligence
Grifols in friendly $3.4 billion takeover of Talecris Biotherapeutics, combining two plasma protein therapy makers to create a world-leading provider.
Combination creates a vertically integrated and diversified international plasma protein therapies company, bringing together complementary geographic…
FTC approved the final consent order settling charges that the Grifols-Talecris merger was anticompetitive, formalizing the divestiture remedy with Kedrion as…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Grifols completed its $3.4B (~$4.0B with debt) acquisition of US plasma-protein therapeutics maker Talecris on June 1, 2011, creating a global plasma-products leader. FTC required divestitures including the Melville fractionation plant.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Grifols, S.A. / Talecris Biotherapeutics Holdings Corp. (this deal) | 2011 | $3.4B | 68 |
| Grifols, S.A. / Novartis Diagnostics (blood transfusion unit) | 2013 | $1.7B | 46 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
← Browse all deals · How we score deals
More: 2011 deals · Hematology deals